| Author
Publication year | Cohort size, | Incidence of de novo anti-HLA DSA | De novo anti-HLA abs, class, DSA frequency | Followup (years) | Incidence of AMR in pts. with de novo anti-HLA Abs | Incidence of GF in total | Incidence of GF in pts. with de novo anti-HLA and anti-HLA DSA |
| | Worthington et al. 2003 [6] | 76 | 10.5% | Class I, 7.9%
Class II, 6.6%
Class I and II, 1.3% | 10 | | 23.7% | 91.7% | | Hourmant et al. 2005 [23] | 1229 | 5.5% | Class I, 0.1%
Class II, 5.4% | 5 | 8% | 8.2% | 16.8%
4.8% | | Terasaki and Cai 2005 [37] | 1564 | | | 2 | | 8% | 16.7% | | Zhang et al. 2005 [39] | 49 | 22.4% | Class I, 10.2%
Class II, 6.1%
Class I + II, 6.1% | 2 | 26.7% | | | | Mihaylova et al. 2006 [26] | 72 | 16.7% | Class I, 9.7%
Class II, 5.6%
Class I + II, 1.4% | 1–5 | 8.3% | 18% | 56.25% | | Mao et al. 2007 [40] | 54 | 27.8% | | 5 | | 46.3% | 65.6%
40.6% | | Lachmann et al. 2009 [9] | 1014 | 9.2% | Class II, 6% | 5.5 | 3.6%
2.4% | 20.9% | 14.7% | | Ntokou et al. 2011 [8] | 597 | 15.4% | Class I, 3.2%
Class II, 11.4%
Class I + II, 0.8% | 1.2–10 | 6%
3.7% | 8% | 15.6%
9.7% | | Wang et al. 2012 [29] | 620 | 6.2% | Class I, 1.5%
Class II, 3.9%
Class I + II 0.8%, DSA | 5 | | 18.4% | 60%
63.2%, DSA | | Ginevri et al. 2012 [28] | 82 | 23.1% | Class I 2.4%, DSA
Class II 13.4%, DSA
Class I + II 7.3%, DSA | 4.3 | 40%
36.7%, DSA | | 13.5%, DSA | | Alberu et al. 2012 [41] | 53 | 32% | Class I 20.7%, DSA
Class II 7.5%, DSA
Class I + II 3.8%, DSA | 2 | 5.7%, DSA | 9.4% | 23.5%, DSA | | Wiebe et al. 2012 [27] | 315 | 14.9% | Class I 0.9%, DSA
Class II 10.2%, DSA
Class I + II 3.8%, DSA | 2.9 ± 6.2 | 5.3%, DSA | 7% | 13.6%, DSA | | Willicombe et al. 2012 [5] | 505 | 18.2% | Class I 5.5% | 5 | 30.6%, DSA | | 14.4%, DSA |
|
|
